GE Buys French Startup to Bolster Breast Cancer Diagnostics
(Bloomberg) -- General Electric Co. has acquired France's Zionexa SAS to bolster its offerings of diagnostic tools for patients with late-stage breast cancer.
The startup and its 24 employees will join GE Healthcare's Pharmaceutical Diagnostics unit, the U.S. manufacturing giant said Thursday. The diagnostics business will also hire 70 more people as part of the transaction. Terms of the deal weren't disclosed.
The purchase adds to GE's offerings in precision health, one of the pillars of Chief Executive Officer Larry Culp's turnaround push along with power equipment and aircraft engines. While Culp has downplayed the potential for major acquisitions in favor of improving the debt-laden conglomerate's existing operations, he has said smaller deals would be part of how GE will “play offense” after years of asset sales and falling revenue.
Boston-based GE plans to expand availability of Zionexa's new molecular imaging agent, which is used as an adjunct to biopsy for patients with advanced breast cancer. U.S. regulators approved the product, known as Cerianna, last year.
“What we're really able to do is scale that product up in the U.S., and that's our focus over the next 12 to 18 months,” Kevin O'Neill, the CEO of GE's diagnostics business, said in an interview.
Imaging agents are radioactive substances that are injected into patients to shed light on what's happening inside the body, using a medical scanner. The agent developed by Aubiere, France-based Zionexa reveals the state of Stage 4 breast cancer tumors and allows for more precise diagnosis and treatments, GE said.
GE was little changed at $13.20 at 9:34 a.m. in New York.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.